NASDAQ · ARCT
Healthcare · Biotechnology
$12.77
Down-$0.24 (-1.81%)
Updated Oct 8, 2026, 2:15 AM
SID Score
4.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · ARCT
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 7, 2026
ARCT closed at $12.77 after 21 trading sessions, down 13.40% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 7, 2026 | $12.71 | $13.40 | $12.59 | $12.765 | 517.81K |
| Oct 6, 2026 | $14.70 | $15.04 | $12.97 | $13.00 | 885.09K |
| Oct 5, 2026 | $13.01 | $15.17 | $12.68 | $14.66 | 1.32M |
| Oct 2, 2026 | $13.33 | $13.65 | $12.79 | $13.03 | 744.85K |
| Oct 1, 2026 | $13.49 | $13.87 | $13.18 | $13.21 | 497.33K |
| Sep 30, 2026 | $13.80 | $14.055 | $13.52 | $13.69 | 593.06K |
| Sep 29, 2026 | $14.45 | $14.47 | $13.26 | $13.70 | 435.87K |
| Sep 28, 2026 | $13.55 | $14.78 | $13.55 | $14.46 | 825.02K |
| Sep 25, 2026 | $14.34 | $14.48 | $13.3005 | $13.85 | 629.88K |
| Sep 24, 2026 | $13.94 | $14.50 | $13.80 | $14.12 | 1.5M |
| Sep 23, 2026 | $14.44 | $14.61 | $13.26 | $13.30 | 1.08M |
| Sep 22, 2026 | $14.65 | $14.687 | $13.88 | $14.38 | 1.07M |
| Sep 21, 2026 | $16.37 | $16.55 | $14.60 | $14.69 | 1M |
| Sep 18, 2026 | $16.685 | $17.75 | $15.92 | $16.03 | 841.47K |
| Sep 17, 2026 | $16.19 | $17.96 | $15.8901 | $16.93 | 1.3M |
| Sep 16, 2026 | $16.00 | $16.3768 | $15.04 | $15.60 | 851.44K |
| Sep 15, 2026 | $15.335 | $15.99 | $14.755 | $15.84 | 556.18K |
| Sep 14, 2026 | $14.62 | $15.53 | $14.42 | $15.29 | 596.19K |
| Sep 11, 2026 | $14.06 | $15.1242 | $14.06 | $14.73 | 496.64K |
| Sep 10, 2026 | $14.29 | $14.33 | $13.12 | $13.98 | 944K |
| Sep 9, 2026 | $15.46 | $15.46 | $14.46 | $14.74 | 723.05K |
The latest Smart Investors Daily articles mentioning ARCT.
Company
Market Activity
Research & News
ARCT research
Company profile and research snapshot.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 24, 2026 | BTIG | Buy | — |
| Sep 24, 2026 | Citigroup | Buy | — |
| Jul 2, 2026 | Freedom Broker | Buy | — |
| Mar 18, 2026 | B. Riley Securities | Buy | — |
| Mar 5, 2026 | Citigroup | Buy | — |
No generated briefing is available yet.
Yahoo · Sep 25, 2026
Arcturus Therapeutics (NASDAQ:ARCT) presented preliminary Phase II data for ARCT-810, its mRNA therapeutic candidate for ornithine transcarbamylase, or OTC, deficiency, while outlining plans to introduce a next-generation delivery platform into the program. OTC deficiency is a urea-cycle disorder i
Benzinga · Sep 24, 2026
Arcturus Therapeutics (ARCT) surged over 6% after sharing positive Phase 2 interim data for its OTC deficiency drug, ARCT-810.
Benzinga · Sep 24, 2026
Citigroup analyst Yigal Nochomovitz upgrades Arcturus Therapeutics (NASDAQ:ARCT) from Neutral to Buy and raises the price target from $8 to $20.
Benzinga · Sep 24, 2026
BTIG analyst Thomas Shrader maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Buy and lowers the price target from $23 to $20.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ARCT.
